Download Library

INVESTORS & MEDIA

INVESTORS
& MEDIA

 
Download Library
Document Type
Cemiplimab Phase 1 CSCC Final Efficacy and Safety Data Poster
Cemiplimab Phase 2 CSCC Primary Analysis Poster
Cemiplimab Phase 2 CSCC Primary Analysis Slides
Cemiplimab Phase 3 Cervical Cancer Poster
A Study of REGN3767, an Anti-LAG-3 Antibody, Alone and in Combination with Cemiplimab (REGN2810), an Anti-PD1 Antibody, in Advanced Cancers
Financial Overview 2018
Financial Overview 2017
2018 Cemiplimab Illustrative Example
Financial Overview 2016
Financial Overview 2015
1
...
NextLast
= add file to Briefcase